Efficacy of anti‑PD‑1 antibody nivolumab in Japanese patients with metastatic renal cell carcinoma: A retrospective multicenter analysis

  • Authors:
    • Kazuyuki Numakura
    • Yohei Horikawa
    • Sachiko Kamada
    • Atsushi Koizumi
    • Taketoshi Nara
    • Syuji Chiba
    • Sohei Kanda
    • Mitsuru Saito
    • Shintaro Narita
    • Takamitsu Inoue
    • Naotake Shimoda
    • Tomonori Habuchi
  • View Affiliations

  • Published online on: June 25, 2019     https://doi.org/10.3892/mco.2019.1887
  • Pages: 320-324
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

To evaluate the efficacy and safety of anti‑PD1 therapy (nivolumab) in advanced renal cell carcinoma (RCC) in a clinical setting. Between March 2013 and January 2018, 33 patients with RCC (27 men and 6 women) were treated with nivolumab. Before anti‑PD1 treatment, 12, 9 and 12 patients received one, two, and three or more therapies, respectively. Objective response, survival rate, and clinical adverse events were evaluated by the revised RECIST criteria (version 1.1). The median patient age was 68 years (range: 37‑79). In total, 14 (42%) patients had an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 while 17 (52%) and two (6%) had an ECOG PS of 1 and 2 or higher, respectively. One (3%), 24 (73%) and eight (24%) were classified as having favorable, intermediate, and poor risk, respectively. The median follow‑up duration after nivolumab initiation was 26 months (range: 1‑131). The median progression‑free and overall survival were 10.3 months and 45.9 months, respectively. Nivolumab was associated with a disease control rate of 58%, with an objective response of 24% (complete response, 1; partial response, 7; stable disease, 11; progressive disease, 10; not assessed, 4). A total of 15 (46%) patients experienced adverse events, of which six were severe (grade 3 or more) and 10 were immunotherapy‑related. This study examined the initial experience of nivolumab administration in Japanese patients with advanced RCC. Our results suggest that nivolumab can achieve acceptable outcomes in a real clinical setting, with outcomes that are comparable to those of clinical trials.
View Figures
View References

Related Articles

Journal Cover

September 2019
Volume 11 Issue 3

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Numakura, K., Horikawa, Y., Kamada, S., Koizumi, A., Nara, T., Chiba, S. ... Habuchi, T. (2019). Efficacy of anti‑PD‑1 antibody nivolumab in Japanese patients with metastatic renal cell carcinoma: A retrospective multicenter analysis. Molecular and Clinical Oncology, 11, 320-324. https://doi.org/10.3892/mco.2019.1887
MLA
Numakura, K., Horikawa, Y., Kamada, S., Koizumi, A., Nara, T., Chiba, S., Kanda, S., Saito, M., Narita, S., Inoue, T., Shimoda, N., Habuchi, T."Efficacy of anti‑PD‑1 antibody nivolumab in Japanese patients with metastatic renal cell carcinoma: A retrospective multicenter analysis". Molecular and Clinical Oncology 11.3 (2019): 320-324.
Chicago
Numakura, K., Horikawa, Y., Kamada, S., Koizumi, A., Nara, T., Chiba, S., Kanda, S., Saito, M., Narita, S., Inoue, T., Shimoda, N., Habuchi, T."Efficacy of anti‑PD‑1 antibody nivolumab in Japanese patients with metastatic renal cell carcinoma: A retrospective multicenter analysis". Molecular and Clinical Oncology 11, no. 3 (2019): 320-324. https://doi.org/10.3892/mco.2019.1887